205 related articles for article (PubMed ID: 32678295)
21. Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer.
Liu Y; Zhang N; Zhang H; Wang L; Duan Y; Wang X; Chen T; Liang Y; Li Y; Song X; Li C; Han D; Chen B; Zhao W; Yang Q
Drug Des Devel Ther; 2020; 14():3535-3545. PubMed ID: 32921987
[TBL] [Abstract][Full Text] [Related]
22. Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapse.
Hartkopf AD; Wallwiener M; Fehm TN; Hahn M; Walter CB; Gruber I; Brucker SY; Taran FA
Ann Oncol; 2015 Jun; 26(6):1155-1160. PubMed ID: 25791636
[TBL] [Abstract][Full Text] [Related]
23. Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk.
Rhodes LV; Antoon JW; Muir SE; Elliott S; Beckman BS; Burow ME
Mol Cancer; 2010 Nov; 9():295. PubMed ID: 21087507
[TBL] [Abstract][Full Text] [Related]
24. Dynamic bioinspired coculture model for probing ER
Pradhan L; Moore D; Ovadia EM; Swedzinski SL; Cossette T; Sikes RA; van Golen K; Kloxin AM
Sci Adv; 2023 Mar; 9(10):eade3186. PubMed ID: 36888709
[TBL] [Abstract][Full Text] [Related]
25. A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Ma CX; Sanchez C; Gao F; Crowder R; Naughton M; Pluard T; Creekmore A; Guo Z; Hoog J; Lockhart AC; Doyle A; Erlichman C; Ellis MJ
Clin Cancer Res; 2016 Jun; 22(11):2650-8. PubMed ID: 26783290
[TBL] [Abstract][Full Text] [Related]
26. Obesity-Altered Adipose Stem Cells Promote Radiation Resistance of Estrogen Receptor Positive Breast Cancer through Paracrine Signaling.
Sabol RA; Villela VA; Denys A; Freeman BT; Hartono AB; Wise RM; Harrison MAA; Sandler MB; Hossain F; Miele L; Bunnell BA
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326381
[TBL] [Abstract][Full Text] [Related]
27. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.
Giuliano M; Herrera S; Christiny P; Shaw C; Creighton CJ; Mitchell T; Bhat R; Zhang X; Mao S; Dobrolecki LE; Al-rawi A; Chen F; Veneziani BM; Zhang XH; Hilsenbeck SG; Contreras A; Gutierrez C; Jeselsohn RM; Rimawi MF; Osborne CK; Lewis MT; Schiff R; Trivedi MV
Breast Cancer Res; 2015 Jan; 17(1):3. PubMed ID: 25572662
[TBL] [Abstract][Full Text] [Related]
28. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.
Fehm T; Hoffmann O; Aktas B; Becker S; Solomayer EF; Wallwiener D; Kimmig R; Kasimir-Bauer S
Breast Cancer Res; 2009; 11(4):R59. PubMed ID: 19664291
[TBL] [Abstract][Full Text] [Related]
29. Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor.
Barok M; Balázs M; Nagy P; Rákosy Z; Treszl A; Tóth E; Juhász I; Park JW; Isola J; Vereb G; Szöllosi J
Cancer Lett; 2008 Feb; 260(1-2):198-208. PubMed ID: 18096313
[TBL] [Abstract][Full Text] [Related]
30. Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study.
Hoffmann O; Aktas B; Goldnau C; Heubner M; Oberhoff C; Kimmig R; Kasimir-Bauer S
Anticancer Res; 2011 Oct; 31(10):3623-8. PubMed ID: 21965788
[TBL] [Abstract][Full Text] [Related]
31. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.
Naderi A; Chia KM; Liu J
Breast Cancer Res; 2011 Apr; 13(2):R36. PubMed ID: 21457548
[TBL] [Abstract][Full Text] [Related]
32. A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III
Ma CX; Suman V; Goetz MP; Northfelt D; Burkard ME; Ademuyiwa F; Naughton M; Margenthaler J; Aft R; Gray R; Tevaarwerk A; Wilke L; Haddad T; Moynihan T; Loprinzi C; Hieken T; Barnell EK; Skidmore ZL; Feng YY; Krysiak K; Hoog J; Guo Z; Nehring L; Wisinski KB; Mardis E; Hagemann IS; Vij K; Sanati S; Al-Kateb H; Griffith OL; Griffith M; Doyle L; Erlichman C; Ellis MJ
Clin Cancer Res; 2017 Nov; 23(22):6823-6832. PubMed ID: 28874413
[No Abstract] [Full Text] [Related]
33. NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients.
Borgen E; Rypdal MC; Sosa MS; Renolen A; Schlichting E; Lønning PE; Synnestvedt M; Aguirre-Ghiso JA; Naume B
Breast Cancer Res; 2018 Oct; 20(1):120. PubMed ID: 30322396
[TBL] [Abstract][Full Text] [Related]
34. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals.
Huang J; Woods P; Normolle D; Goff JP; Benos PV; Stehle CJ; Steinman RA
Breast Cancer Res Treat; 2017 Jan; 161(2):229-243. PubMed ID: 27853906
[TBL] [Abstract][Full Text] [Related]
36. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
37. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer.
Daskalaki A; Agelaki S; Perraki M; Apostolaki S; Xenidis N; Stathopoulos E; Kontopodis E; Hatzidaki D; Mavroudis D; Georgoulias V
Br J Cancer; 2009 Aug; 101(4):589-97. PubMed ID: 19623181
[TBL] [Abstract][Full Text] [Related]
38. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
[TBL] [Abstract][Full Text] [Related]
39. BMP9 regulates cross-talk between breast cancer cells and bone marrow-derived mesenchymal stem cells.
Wan S; Liu Y; Weng Y; Wang W; Ren W; Fei C; Chen Y; Zhang Z; Wang T; Wang J; Jiang Y; Zhou L; He T; Zhang Y
Cell Oncol (Dordr); 2014 Oct; 37(5):363-75. PubMed ID: 25209393
[TBL] [Abstract][Full Text] [Related]
40. Influence of endocrine therapy on the ratio of androgen receptor (AR) to estrogen receptor (ER) positive circulating epithelial tumor cells (CETCs) in breast cancer.
Pizon M; Lux D; Pachmann U; Pachmann K; Schott D
J Transl Med; 2018 Dec; 16(1):356. PubMed ID: 30547831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
